These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35355980)

  • 1. Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
    Clubb JHA; Kudling TV; Heiniö C; Basnet S; Pakola S; Cervera Carrascón V; Santos JM; Quixabeira DCA; Havunen R; Sorsa S; Zheng V; Salo T; Bäck L; Aro K; Tulokas S; Loimu V; Hemminki A
    Front Immunol; 2022; 13():794251. PubMed ID: 35355980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
    Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer.
    Kudling TV; Clubb JHA; Pakola S; Quixabeira DCA; Lähdeniemi IAK; Heiniö C; Arias V; Havunen R; Cervera-Carrascon V; Santos JM; Sutinen E; Räsänen J; Borenius K; Mäyränpää MI; Aaltonen E; Sorsa S; Hemminki O; Kanerva A; Verschuren EW; Ilonen I; Hemminki A
    Oncoimmunology; 2023; 12(1):2241710. PubMed ID: 37546696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
    Clubb JHA; Kudling TV; Girych M; Haybout L; Pakola S; Hamdan F; Cervera-Carrascon V; Hemmes A; Grönberg-Vähä-Koskela S; Santos JM; Quixabeira DCA; Basnet S; Heiniö C; Arias V; Jirovec E; Kaptan S; Havunen R; Sorsa S; Erikat A; Schwartz J; Anttila M; Aro K; Viitala T; Vattulainen I; Cerullo V; Kanerva A; Hemminki A
    Front Immunol; 2023; 14():1060540. PubMed ID: 36817448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition.
    Cervera-Carrascon V; Quixabeira DCA; Santos JM; Havunen R; Zafar S; Hemminki O; Heiniö C; Munaro E; Siurala M; Sorsa S; Mirtti T; Järvinen P; Mildh M; Nisen H; Rannikko A; Anttila M; Kanerva A; Hemminki A
    Oncoimmunology; 2020 May; 9(1):1761229. PubMed ID: 32923123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1.
    Cervera-Carrascon V; Quixabeira DCA; Santos JM; Havunen R; Milenova I; Verhoeff J; Heiniö C; Zafar S; Garcia-Vallejo JJ; van Beusechem VW; de Gruijl TD; Kalervo A; Sorsa S; Kanerva A; Hemminki A
    Front Immunol; 2021; 12():706517. PubMed ID: 34367166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
    Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.
    Rosewell Shaw A; Porter CE; Watanabe N; Tanoue K; Sikora A; Gottschalk S; Brenner MK; Suzuki M
    Mol Ther; 2017 Nov; 25(11):2440-2451. PubMed ID: 28974431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity.
    Mei S; Peng S; Vong EG; Zhan J
    Int Immunopharmacol; 2024 Feb; 128():111579. PubMed ID: 38278066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus.
    Hirvinen M; Rajecki M; Kapanen M; Parviainen S; Rouvinen-Lagerström N; Diaconu I; Nokisalmi P; Tenhunen M; Hemminki A; Cerullo V
    Hum Gene Ther; 2015 Mar; 26(3):134-44. PubMed ID: 25557131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.
    Santos J; Heiniö C; Quixabeira D; Zafar S; Clubb J; Pakola S; Cervera-Carrascon V; Havunen R; Kanerva A; Hemminki A
    Cells; 2021 Apr; 10(5):. PubMed ID: 33922052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer.
    Jhawar SR; Wang SJ; Thandoni A; Bommareddy PK; Newman JH; Marzo AL; Kuzel TM; Gupta V; Reiser J; Daniels P; Schiff D; Mitchell D; LeBoeuf NR; Simmons C; Goyal S; Lasfar A; Guevara-Patino JA; Haffty BG; Kaufman HL; Silk AW; Zloza A; Giurini EF
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37433716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers.
    Heiniö C; Clubb J; Kudling T; Quixabeira D; Cervera-Carrascon V; Havunen R; Grönberg-Vähä-Koskela S; Santos JM; Tapper J; Kanerva A; Hemminki A
    Diseases; 2022 Aug; 10(3):. PubMed ID: 35997357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.
    Santos JM; Cervera-Carrascon V; Havunen R; Zafar S; Siurala M; Sorsa S; Anttila M; Kanerva A; Hemminki A
    Mol Ther; 2018 Sep; 26(9):2243-2254. PubMed ID: 30017877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
    Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment.
    Meng Y; Liu H; Zhu H; Zhang W; Sun D; Han X; Liu Y; Luo G
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.
    Mochizuki Y; Tazawa H; Demiya K; Kure M; Kondo H; Komatsubara T; Sugiu K; Hasei J; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
    Cancer Immunol Immunother; 2021 May; 70(5):1405-1417. PubMed ID: 33151368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy.
    Lv P; Chen X; Fu S; Ren E; Liu C; Liu X; Jiang L; Zeng Y; Wang X; Liu G
    Biomater Sci; 2021 Nov; 9(22):7392-7401. PubMed ID: 34751685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control.
    Quixabeira DCA; Zafar S; Santos JM; Cervera-Carrascon V; Havunen R; Kudling TV; Basnet S; Anttila M; Kanerva A; Hemminki A
    Front Immunol; 2021; 12():674400. PubMed ID: 34084172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.